<DOC>
	<DOCNO>NCT00323583</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , oxaliplatin , leucovorin 5-fluoruracil , work different way separately combination stop tumor cell divide stop grow die . The use metronomic dosing chemotherapy minimize side effect increase efficacy anti-angiogenic effect . The pilot study demonstrate promising response patient . It yet know effective drug dose combination treat advanced pancreatic cancer . PURPOSE : This non-randomized phase II trial study give weekly dos paclitaxel , oxaliplatin , leucovorin 5-fluorouracil together second third-line therapy treat patient locally advanced unresectable metastatic adenocarcinoma pancreas follow demonstrated progression first-line gemcitabine .</brief_summary>
	<brief_title>Weekly Dosing Integrative Chemotherapy Combination Treat Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - The primary objective determine effectiveness chemotherapy combination improve experience advance pancreatic cancer - Pain control aspects quality life - Reduction tumor size stabilization tumor growth - Progression free survival - Overall survival - The secondary objective determine safety chemotherapy combination monitor manage potential side effect DOSE REGIMEN OUTLINE : Paclitaxel 60mg/m2 IV weekly ; Oxaliplatin 50mg/m2 IV weekly ; Leucovorin 20 mg/m2 IV weekly , minimum 40 mg ; 5FU 425mg/m2 IV weekly ; Weekly 12 week ; Calcium magnesium 1gram IV prior Oxaliplatin therapy ; Glutathione 1500mg/m2 prior Oxaliplatin DURATION OF STUDY PERIOD : Patient continue study treatment death , disease progression , unacceptable toxicity , patient refusal , treatment delay great 3 week , 12 week initially , continue discretion investigator . EXPECTED NUMBER OF PATIENTS : A total 80 patient ( 40 second line treatment 40 third line great treatment ) enrol study beginning May 2006 . QUALITY OF LIFE : Quality life assess baseline , month treatment end study therapy .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS Patients pathologicallyproven pancreatic adenocarcinoma , 1. candidate surgery 2. candidate radiation therapy 3. fail gemcitabinebased chemotherapy regimen Gender Eligible Study : Both Prior Therapy : For advanced disease allow ; Oxaliplatin 5FU allow subset analysis do group patient ; Tarceva and/or Erbitux allow , subset analysis do . Allergies : No know allergy one study drug PATIENT CHARACTERISTICS : No CNS metastases No peripheral neuropathy &gt; grade 2 ECOG Performance Status &lt; =2 Age ≤ 65 No serious concomitant illness Fully recover prior therapy Lower Age Limit : &gt; 18 Upper Age Limit : ≤ 65 Laboratory : ANC &gt; 1500 Platelets &gt; 75,000 Creatinine &lt; =2.0 Other : For female patient childbearing potential , neither pregnant breastfeeding , active contraception Performance state &gt; =3 Uncontrolled serious concomitant disease Radiotherapy within 6 week Cycle 1‚ Day 1 Surgery within 2 week Cycle 1‚ Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Cancer Alternative Therapies</keyword>
	<keyword>Living Cancer</keyword>
</DOC>